

# Author Index

VOLUME 27, 2001

- Adachi, Tomoko, 149  
 Adix, Leah, 277  
 Agnelli, Giancarlo, 41  
 Aksamit, Timothy R., 47  
 Alban, Susanne, 503  
 Antonucci, Emilia, 543  
 Arai, Yoshimi, 149  
 Asahina, Toshihiko, 67, 115  
 Auer, Wilfried, 395  
 Avgerinos, George C., 357
- Barbui, Tiziano, 593  
 Barnes, Christopher S., 337  
 Baumann, Hanno, 445  
 Belayet, Hossain, 79  
 Bisio, Antonella, 473  
 Bjørklid, Eirik, 605  
 Bjørn, Søren E., 373  
 Boedecker, Berthold G.D., 385  
 Bolton-Maggs, Paula H.B., 269  
 Boneu, Bernard, 519  
 Bounameaux, Henri, 25  
 Brandis, Matthias, 287  
 Brandt, Natasha, 349  
 Breddin, H. Klaus, 513  
 Bretschneider, Ellen, 489  
 Buchanan, George R., 277  
 Bussel, James B., 245  
 Butcher, Matthew S., 15
- Casu, Benito, 437
- Dahlems, Ulrike, 337  
 Dame, Christof, 215  
 de Jonge, Evert, 569, 639, 667  
 de Moerloose, Philippe, 519  
 de Monyé, Wouter, 32  
 Dickerhoff, Roswitha, 269  
 Dinger, Jürgen, 169  
 Dorner, Friedrich, 395
- Ebina, Yasuhiko, 121  
 Echelard, Yann, 405  
 Erhardsen, Elisabeth, 373
- Falanga, Anna, 593  
 Falciani, Michela, 543
- Fareed, Jawed, 495  
 Francis, Charles W., 657  
 Frech, Matthias, 337  
 Fujimoto, Seiichiro, 121, 143
- Gando, Satoshi, 585  
 Gellissen, Gerd, 311, 337, 357  
 Gensini, Gian Franco, 543  
 Giese, Christine, 495  
 Gorelick, Kenneth J., 357  
 Goto, Junko, 67  
 Gritsch, Herbert, 395  
 Grohmann, Astrid, 237, 287  
 Guerrini, Marco, 473
- Hack, C. Erik, 633  
 Hardaway, Robert M., 577  
 Harenberg, Job, 495, 513, 531  
 Harms, Anja, 253  
 Hashiguchi, Kazunari, 149  
 Hata, Akira, 143  
 Hofmann, Uwe R., 337  
 Hoppensteadt, Debra, 495  
 Horan, John T., 657  
 Hoylaerts, Marc F., 337  
 Huhle, Günther, 495  
 Huisman, Menno V., 513  
 Hull, Russell D., 15
- Ibara, Satoshi, 87  
 Ikenoue, Tsuyomu, 161  
 Isoda, Haruo, 131  
 Iwaki, Takayuki, 79, 155  
 Iwata, Ginko, 93
- Jørgensen, Tom B., 373  
 Jurlander, Birgit, 373
- Kabus, Maria, 169  
 Kagami, Kazuo, 155  
 Kaiser, Phoebe, 495  
 Kanamori, Masao, 143  
 Kanayama, Naohiro, 79, 87, 99, 107, 115, 131, 137, 155  
 Karch, Helge, 207  
 Kato, Emi-Hirayama, 121, 143  
 Kaufmehl, Klaus, 237, 253
- Kearon, Clive, 3  
 Kemkes-Matthes, Bettina, 551  
 Kesecioglu, Jozef, 667  
 Khatun, Selina, 79  
 Kirchmaier, Clause M., 513  
 Kjalke, Marianne, 373  
 Klausen, Niels K., 373  
 Knöfler, Ralf, 169  
 Kobashi, Gen, 121, 143  
 Kobayashi, Hiroshi, 67, 99  
 Kobayashi, Takao, 79, 87, 99, 107, 115, 131, 137, 155, 161  
 Kojima, Tetsuhito, 155  
 Kondo, Kiyotaro, 143  
 Krafft, Bianca, 337  
 Kunz, Dagmar, 229
- Lauterbach, Ingrid, 169  
 Leben, Rainer, 349  
 Levi, Marcel, 569, 639, 667  
 Levy, Jerrold H., 405  
 Li, Jin-Ping, 437  
 Lindahl, Ulf, 437
- Maeda, Makoto, 87  
 Mah, Andrew F., 15  
 Maki, Masahiro, 161  
 Mammen, Eberhard F., 1, 63, 309, 433, 565  
 Markwardt, Fritz, 523  
 Mastushita, Tadashi, 155  
 Matsuura, Toshiki, 115  
 Matsuyama, Kaoru, 87  
 Mattes, Ralf, 325  
 Matthes, Karl J., 551  
 Melber, Karl, 349  
 Menssen, Hans D., 349  
 Michiels, Jan J., 1  
 Mitterer, Artur, 395  
 Morikawa, Mamoru, 121  
 Müller, Diane, 169  
 Müller, Frank, 349  
 Mundt, Wolfgang, 395
- Naggi, Annamaria, 437, 465, 483  
 Nakayama, Takeyuki, 155  
 Nishiguchi, Tomizo, 87

- Nomura, Yuka, 155  
Novak, Götz, 537
- Ohashi, Ryouta, 107  
Ohta, Hiroaki, 149  
Okada, Yoshichika, 67  
Oldenburg, Johannes, 313, 417  
Oreste, Pasqua, 437  
Østergaard, Per B., 373  
Østerud, Bjarne, 605
- Palumbo, Manlio, 483  
Papendieck, Adam, 337, 357  
Pattynama, Peter M.T., 32  
Perrier, Arnaud, 25  
Persson, Egon, 373  
Piazolo, Lukas, 531  
Pichler, Ludwig, 395  
Pineo, Graham F., 15  
Plaimauer, Barbara, 395  
Prandoni, Paolo, 9  
Prisco, Domenico, 543  
Proesmans, Willem, 201  
Prüfer, Friederike H.A., 287
- Rexen, Per, 373  
Rossi, Romina, 41  
Rupprecht, Edgar, 169
- Saito, Hidehiko, 155  
Sakuragi, Noriaki, 121  
Schlokat, Uwe, 395  
Schrör, Karsten, 489  
Schwaab, Rainer, 313, 417  
Schwarz, Hans-Peter, 395  
Severin, Thomas, 293  
Shido, Koichi, 143  
Shimada, Shigeki, 121  
Shu, Fang, 99  
Sissi, Claudia, 483  
Sonaglia, Francesco, 41  
Stein, Paul D., 15  
Sturiale, Luisa, 465  
Sugimura, Motoi, 99, 107, 137  
Sugiura, Isamu, 155  
Sumimoto, Kazuhiro, 79  
Sutor, Anton H., 93, 183, 237, 253, 287, 293  
Suzuki, Shigenori, 93
- Takamatsu, Junki, 155  
Taut-Sack, Heike, 169  
Taylor, C. Mark, 185  
Taylor, Fletcher B., Jr., 619  
ten Cate, Hugo, 569  
Terao, Toshihiko, 67, 87, 115, 131, 137, 161  
Thiel, Eckhard, 349
- Thim, Lars, 373  
Thomas, Kathy B., 287  
Toh, Cheng Hock, 653  
Tokunaga, Naoki, 131, 137  
Tolle, Alexander R., 513  
Torri, Giangiacomo, 437, 465, 473, 483  
Turecek, Peter L., 395  
Turner, Brian G., 357
- van der Poll, Tom, 569, 639, 667  
Vasquez, Yvonne, 577  
Vora, Ajay J., 269
- Walenga, Jeanine M., 495  
Weisinger, Andrew, 405  
Weissbach, Gerhard, 169  
Weydemann, Ulrike, 357  
Williams, Charles H., 577  
Wündisch, Thomas, 237
- Yamada, Hideto, 121, 143  
Yamada, Takahiro, 121  
Yamamoto, Yukako, 155
- Zimmerhackl, Lothar B., 287  
Ziomek, Carol A., 405  
Zipfel, Peter F., 191  
Zokai, Kaweh, 531  
Zoppetti, Giorgio, 437

Is \_\_

le \_\_

ll \_\_

# Subject Index

VOLUME 27, 2001

- Abortion, spontaneous. *See* Miscarriage
- Activated partial thromboplastin time  
for monitoring of hirudin and direct thrombin inhibitors, 537  
in pregnant mice injected with activated protein C, 99
- Activated platelet-derived phospholipids, as thrombogenic factors in intraplacental coagulation, 107
- Aldehydes, peptide, as thrombin indicator, 523
- All-*trans* retinoic acid, for acute leukemia, 593
- Amino acids, alignment of, DNA sequence analysis of protein S deficiency and, 155
- Anemia, aplastic, thrombopoietin in, 222
- Angiography, pulmonary  
for pulmonary embolism diagnosis, cost-effectiveness of, 15  
for thromboembolism diagnosis, in medical intensive care unit, 47
- Angiotensinogen, T235 variant of angiotensin gene as risk factor for preeclampsia and, 143
- Annexin V, as antithrombogenic factor in intraplacental coagulation, 107
- Anticoagulant factors. *See also specific factors*  
anticoagulant pathway responses in disseminated intravascular coagulation and, 619  
concentrates of, in disseminated intravascular coagulation, 667
- Anticoagulants. *See also specific anticoagulants*  
for postoperative deep venous thrombosis, 9  
for prevention of intrauterine growth restriction with intraplacental coagulation, 107
- Antifibrinolytic agents, for acute leukemia, 593
- Anti- $\beta$ 2-glycoprotein I antibody, recurrent pregnancy loss associated with thrombophilia and, 121
- Antiphospholipid antibodies  
recurrent pregnancy loss associated with thrombophilia and, 121  
as thrombogenic factors in intraplacental coagulation, 107
- Antithrombin  
deficiency of, recurrent pregnancy loss associated with thrombophilia and, 121  
in disseminated intravascular coagulation, 667  
obstetrical disseminated intravascular coagulation and, 161  
predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137  
recombinant  
for cardiovascular disorders, 405  
production of, 405  
sulfation effects on antithrombin-thrombin/Factor Xa interactions in semisynthetic low molecular weight heparin, 483
- Antithrombin binding sequence, combined quantitative magnetic resonance spectroscopy for characterization of heparin preparations, 473
- Antithrombotic agents, saratin as, 337
- Aplastic anemia, thrombopoietin in, 222
- Arterial thromboembolism. *See also* Thromboembolism  
molecular biology of blood coagulation and, 313
- Autotoxins, septic shock and, 577
- Bernard-Soulier syndrome, thrombopoietin in, 222
- Biomaterials, regioselectively sulfated and acetylated coatings of, to reduce platelet and plasma protein adhesion, 445
- Bleeding  
in acute leukemia, 593  
in idiopathic thrombocytopenic purpura, in children, 277  
in immune thrombocytopenia, retrospective and prospective survey in Germany, 253  
monitoring patients treated with low molecular weight heparin and, 519  
postpartum, factor XII deficiency related to recurrent miscarriage and, 115  
protein Z and, 551  
reduction in thrombus extension and clinical end points after certoparin treatment for deep venous thrombosis and, 513  
vitamin K deficiency and, during perinatal and infantile period, 93
- Blood coagulation  
beginning and regulation of, 605  
cytokine regulation of disseminated intravascular coagulation and, 639  
defects of, due to vitamin K deficiency, 93  
diarrhea-associated hemolytic-uremic syndrome and, 201  
effect of thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonist in ex vivo human experimental thrombosis model and, 531  
effects of heparin-binding protein on, 495  
intraplacental, in intrauterine growth restriction, 107  
molecular biology of, 313  
predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137  
protein Z and, 551

- Blood tests  
for end-point measurement, in deep venous thrombosis prevention studies, 41  
on recombinant hirudin, 349
- Breast feeding, infantile vitamin K deficiency and, 93
- Cancer, complement factor H and, 191
- Cardiopulmonary bypass, recombinant antithrombin and, 405
- CD44, edematous changes in endometrial stroma during implantation and, 67
- Cellulose, regioselectively sulfated and acetylated coatings of biomaterials to reduce platelet and plasma protein adhesion and, 445
- Children. *See also* Infants  
diarrhea-associated hemolytic-uremic syndrome in, role of coagulation and fibrinolysis in pathogenesis of, 201  
recombinant tissue-plasminogen activator in, 169  
thrombocytopenia in. *See* Thrombocytopenia, in children
- Chitosan, regioselectively sulfated and acetylated coatings of biomaterials to reduce platelet and plasma protein adhesion and, 445
- Chondroitin sulfate, regioselectively sulfated and acetylated coatings of biomaterials to reduce platelet and plasma protein adhesion and, 445
- c-mpl*, thrombopoietin in thrombocytopenias of childhood and, 215
- Coagulation. *See* Blood coagulation
- Coagulopathy  
of acute leukemia, 593  
consumptive. *See* Disseminated intravascular coagulation
- Cold stress, localized, retroplacental hemorrhage related to, in rats, 79
- Collagen  
type III, edematous changes in endometrial stroma during implantation and, 67  
von Willebrand factor-dependent platelet adhesion to, saratin inhibition of, 337  
von Willebrand factor in diarrhea-associated hemolytic-uremic syndrome and, 287
- Complement factor H  
deficiency of, hemolytic-uremic syndrome with, 185  
physiology and pathophysiology of, 191
- Computed tomography, spiral, for pulmonary embolism diagnosis, cost-effectiveness of, 15
- Consumptive coagulopathy. *See* Disseminated intravascular coagulation
- Cord blood, variation of des-gamma-carboxyprothrombin levels in, throughout gestation, 87
- Cost, of idiopathic thrombocytopenic purpura, in children, 277
- Cost-effectiveness, of diagnostic strategies for pulmonary embolism, 15  
in outpatients, 25
- Cytokines  
diarrhea-associated hemolytic-uremic syndrome and, 201  
in disseminated intravascular coagulation  
in acute leukemia, 593  
pathogenesis and, 569  
regulatory role of, 639  
tissue factor pathway and, 605
- Deep venous thrombosis  
certoparin treatment for, reduction in thrombus extension and clinical end points after, 513  
clinical course of, long-term, 9  
hirudins for prophylaxis and treatment of, 543  
low molecular weight heparin for, monitoring patients treated with, 519  
in postoperative patients, noninvasive diagnosis of, 3  
in pregnancy and puerperium, clinical study of, 149  
prevention of, end points in studies of, 41  
recurrent, detection of, 9
- Des-gamma-carboxyprothrombin, variation of cord blood levels, throughout gestation, 87
- Diarrhea, hemolytic-uremic syndrome associated with role of coagulation and fibrinolysis in pathogenesis of, 201  
von Willebrand factor in, 287
- D-Dimer  
in disseminated intravascular coagulation, 657  
for end-point measurement, in deep venous thrombosis prevention studies, 41  
predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137  
for pulmonary embolism diagnosis, 25  
cost-effectiveness of, 15  
recombinant tissue-plasminogen activator in children and, 169  
for thromboembolism diagnosis, in medical intensive care unit, 47
- Disseminated intravascular coagulation  
in acute leukemia, 593  
anticoagulant factor concentrates in, 667  
anticoagulant pathway responses in, 619  
fibrin degradation products, fibrin monomer, and soluble fibrin in, 657  
fibrinolysis in, 633  
laboratory testing in, 653  
nonovert, anticoagulant pathway responses in, 619  
obstetrical  
diagnosis and management of, 161  
tissue factor pathway in disseminated intravascular coagulation and, 605  
pathogenesis of, 569  
regulatory role of cytokines in, 639  
in sepsis, 577  
tissue factor pathway in, 605  
in trauma patients, 585
- DNA sequence analysis, of protein S deficiency, 155
- Ecarin clotting time, for monitoring of hirudin and direct thrombin inhibitors, 537
- Echocardiography, for thromboembolism diagnosis, in medical intensive care unit, 47
- Eclampsia, angiospastic syndrome of pregnancy and, 131
- Edema, of endometrial stroma, during implantation, 67
- Elastic stockings, for postoperative deep venous thrombosis, 9
- Electroluminescence immunoassay, variation of des-gamma-carboxyprothrombin levels in cord blood throughout gestation and, 87
- Endometrium  
stroma of, edematous changes during implantation, 67

- vessels of, edematous changes in endometrial stroma during implantation and, 67
- Endothelium
  - anticoagulant pathway responses in disseminated intravascular coagulation and, 619
  - tissue factor pathway in disseminated intravascular coagulation and, 605
- Endotoxemia, anticoagulant pathway responses in disseminated intravascular coagulation and, 619
- Endotoxins
  - cytokine regulation of disseminated intravascular coagulation and, 639
  - in disseminated intravascular coagulation, 657
  - septic shock and, 577
- Enterocolitis, hemolytic-uremic syndrome with complement factor H deficiency and, 185
- Enterohemorrhagic *Escherichia coli*, hemolytic-uremic syndrome associated with, role of virulence factors in, 207
- Enzyme-linked immunoassays, of recombinant hirudin, 349
- Escherichia coli*
  - enterohemorrhagic *Escherichia coli*-associated hemolytic-uremic syndrome and, role of virulence factors in, 207
  - K5 polysaccharide of
    - glycosaminoglycan generation from, 437
    - MALDI mass spectrometry as tool for characterizing glycosaminoglycans, 465
  - sepsis caused by, anticoagulant pathway responses in disseminated intravascular coagulation and, 619
  - tissue-type plasminogen activator production in, 325
- Factor V Leiden mutation, recurrent pregnancy loss associated with thrombophilia and, 121
- Factor VII, recombinant, activated, characterization, manufacturing, and clinical development of, 373
- Factor VIII
  - molecular biology of blood coagulation and, 313
  - recombinant, production of, 385
- Factor Xa
  - anticoagulant pathway responses in disseminated intravascular coagulation and, 619
  - cellular effects on vascular smooth muscle cells, inhibition by heparins, 489
  - sulfation effects on antithrombin-thrombin/Factor Xa interactions in semisynthetic low molecular weight heparin, 483
- Factor XII, deficiency of
  - recurrent miscarriage related to, 115
  - recurrent pregnancy loss associated with thrombophilia and, 121
- Fanconi anemia, thrombopoietin in, 220
- Fetus. *See also* Pregnancy
  - alloimmune thrombocytopenia in, 245
  - autoimmune thrombocytopenia in, thrombopoietin in, 220
- Fibrin, in disseminated intravascular coagulation, 657
- Fibrinogen degradation products, for pulmonary embolism diagnosis, in outpatients, 25
- Fibrinogen leg scanning, for deep venous thrombosis, in postoperative patients, 3
- Fibrinolysis
  - cytokine regulation of disseminated intravascular coagulation and, 639
  - diarrhea-associated hemolytic-uremic syndrome and, 201
  - in disseminated intravascular coagulation, 633
  - disseminated intravascular coagulation in acute leukemia and, 593
  - fibrinolysis in disseminated intravascular coagulation and, 633
  - inhibition of, disseminated intravascular coagulation and, 585
  - predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137
- Fluorescence labeling, regioselectively sulfated and acetylated coatings of biomaterials to reduce platelet and plasma protein adhesion and, 445
- Gastroenteritis, von Willebrand factor in diarrhea-associated hemolytic-uremic syndrome and, 287
- Gene therapy, of hemophilia, 417
- Genetic diagnosis, DNA sequence analysis of protein S deficiency and, 155
- Genotype, phenotype correlated with, molecular biology of blood coagulation and, 313
- Glomerulonephritis, membranoproliferative, 191
- Glucocorticoids, for immune thrombocytopenia, 253
- Glycoproteins, effect of thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonist in ex vivo human experimental thrombosis model and, 531
- Glycosaminoglycans
  - generation from *Escherichia coli* K5 capsular polysaccharide, 437
  - MALDI mass spectrometry as tool for characterizing, 465
  - sulfation effects on antithrombin-thrombin/Factor Xa interactions in semisynthetic low molecular weight heparin, 483
- Hansenula polymorpha*
  - hirudin derived from, production and clinical development of, 357
  - sarin production using, 337
- Helical computed tomography, contrast-enhanced, of pulmonary arteries, 33
- HELLP syndrome, angiospastic syndrome of pregnancy and, 131
- Hemolytic-uremic syndrome
  - associated with enterohemorrhagic *Escherichia coli*, role of virulence factors in, 207
  - complement factor H and deficiency of, 185
  - physiology and pathophysiology of, 191
  - diarrhea-associated
    - role of coagulation and fibrinolysis in pathogenesis of, 201
    - von Willebrand factor in, 287
- Hemophilia
  - gene therapy of, 417
  - molecular biology of blood coagulation and, 313
- Heparan sulfate
  - glycosaminoglycan generation from *Escherichia coli* K5 capsular polysaccharide and, 437
  - regioselectively sulfated and acetylated coatings of biomaterials to reduce platelet and plasma protein adhesion and, 445



- Heparin  
 for acute leukemia, 593  
 combined quantitative magnetic resonance spectroscopy  
 for characterization of preparations, 473  
 glycosaminoglycan generation from *Escherichia coli* K5  
 capsular polysaccharide and, 437  
 low molecular weight  
 effects of heparin-binding protein on blood coagulation  
 and platelet function and, 495  
 inhibition of cellular effects of Factor Xa on vascular  
 smooth muscle cells, 489  
 monitoring patients treated with, 519  
 for prophylaxis and treatment of venous  
 thromboembolism, 543  
 reduction in thrombus extension and clinical end points  
 after certoparin treatment for deep venous thrombosis  
 and, 513  
 semisynthetic, sulfation effects on antithrombin-  
 thrombin/Factor Xa interactions in, 483  
 molecular weight-dependent influence on form of tissue  
 factor pathway inhibitor circulating in plasma, 503  
 recombinant tissue-plasminogen activator in children and,  
 169  
 regioselectively sulfated and acetylated coatings of  
 biomaterials to reduce platelet and plasma protein  
 adhesion and, 445  
 resistance to, recombinant antithrombin and, 405  
 synthetic, 161  
 thrombocytopenia induced by  
 in children, 293  
 effects of heparin-binding protein on blood coagulation  
 and platelet function and, 495  
 hirudins for prophylaxis and treatment of  
 thromboembolism and, 543
- Hepatoblastoma, thrombopoietin in, 222
- Hepatopathy, thrombopoietin in, 222
- Hirudin  
 clinical monitoring of, 537  
*Hansenula polymorpha*-derived, production and clinical  
 development of, 357  
 production of, 523  
 for prophylaxis and treatment of venous  
 thromboembolism, 543  
 recombinant, automated blood testing of, 349
- HIV infection, thrombopoietin in, 222
- Hypercoagulability  
 disseminated intravascular coagulation in acute leukemia  
 and, 593  
 in intrauterine growth restriction, 107
- Hypertension, hemolytic-uremic syndrome with complement  
 factor H deficiency and, 185
- Idiopathic thrombocytopenic purpura  
 in children, outcome measures and treatment endpoints in,  
 277  
 von Willebrand factor in diarrhea-associated hemolytic-  
 uremic syndrome and, 287
- <sup>125</sup>I fibrinogen leg scanning, for end-point measurement, in  
 deep venous thrombosis prevention studies, 41
- Immunoglobulins, for immune thrombocytopenia, 245, 253
- Immunohistochemical staining, of edematous changes in  
 endometrial stroma during implantation, 67
- Immunological platelet counting, in thrombocytopenia, 229
- Immunophenotyping, of recombinant hirudin, 349
- Impedance plethysmography  
 for deep venous thrombosis, in postoperative patients, 3  
 for end-point measurement, in deep venous thrombosis  
 prevention studies, 41  
 for thromboembolism diagnosis, in medical intensive care  
 unit, 47
- Inducible NO synthase, edematous changes in endometrial  
 stroma during implantation and, 67
- Infants  
 infections in, tissue factor pathway in disseminated  
 intravascular coagulation and, 605  
 newborn  
 alloimmune thrombocytopenia in, 245  
 autoimmune thrombocytopenia in, thrombopoietin in, 220  
 variation of des-gamma-carboxyprothrombin levels in  
 cord blood throughout gestation and, 87  
 vitamin K deficiency in, 93
- Inflammation  
 anticoagulant factor concentrates in disseminated  
 intravascular coagulation and, 667  
 disseminated intravascular coagulation and, 585
- Intensive care unit, medical, thromboembolism occurrence  
 and diagnosis in, 47
- Interleukin-8, edematous changes in endometrial stroma  
 during implantation and, 67
- Intracranial hemorrhage, in alloimmune thrombocytopenia,  
 245
- Intrauterine growth restriction  
 intraplacental coagulation in, 107  
 phosphatidylserine-induced, in mice, prevention by  
 activated protein C, 99
- Intravenous gamma globulin, for alloimmune  
 thrombocytopenia, in fetus and newborn, 245
- Kawasaki disease, thrombopoietin in, 222
- Kinins, factor XII deficiency related to recurrent miscarriage  
 and, 115
- Laboratory testing. *See also* Blood tests  
 in disseminated intravascular coagulation, 653
- Leukemia, acute, disseminated intravascular coagulation in,  
 593
- Leukocytes, diarrhea-associated hemolytic-uremic syndrome  
 and, 201
- Lifestyle, T235 variant of angiotensin gene as risk factor for  
 preeclampsia and, 143
- Lipoproteins, molecular weight-dependent influence of  
 heparin on form of tissue factor pathway inhibitor  
 circulating in plasma and, 503
- Locus of enterocyte effacement, Enterohemorrhagic  
*Escherichia coli*-associated hemolytic-uremic syndrome  
 and, 207
- Magnetic resonance angiography, angiospastic syndrome of  
 pregnancy and, 131
- Magnetic resonance imaging, for thromboembolism  
 diagnosis, in medical intensive care unit, 47
- Magnetic resonance spectroscopy, combined quantitative  
 magnetic resonance spectroscopy for characterization  
 of heparin preparations, 473

- MALDI mass spectrometry, as tool for characterizing glycosaminoglycans, 465
- Malignancy, disseminated intravascular coagulation in, 593
- Marder score, reduction in thrombus extension and clinical end points after certoparin treatment for deep venous thrombosis and, 513
- Mast cell tryptase, edematous changes in endometrial stroma during implantation and, 67
- Maternal diseases, variation of des-gamma-carboxyprothrombin levels in cord blood throughout gestation and, 87
- Medical intensive care unit, thromboembolism occurrence and diagnosis in, 47
- Membranoproliferative glomerulonephritis type II, 191
- Meningococcal disease, tissue factor pathway in disseminated intravascular coagulation and, 605
- Meningococcosis, recombinant tissue-plasminogen activator in children and, 169
- Methylene tetrahydrofolate reductase, recurrent pregnancy loss associated with thrombophilia and, 121
- Miscarriage, recurrent  
factor XII deficiency related to, 115  
thrombophilia associated with, 121
- Mitogenesis, inhibition of cellular effects of Factor Xa on vascular smooth muscle cells by heparins, 489
- Molecular weight distributions, MALDI mass spectrometry as tool for characterizing glycosaminoglycans, 465
- Monocytes, tissue factor pathway in disseminated intravascular coagulation and, 605
- Multiple organ dysfunction syndrome, disseminated intravascular coagulation and, 585  
fibrinolysis in, 633  
pathogenesis of, 569
- Neutrophil elastase, edematous changes in endometrial stroma during implantation and, 67
- Newborn infants. *See* Infants, newborn
- Noninvasive testing  
for deep venous thrombosis, in postoperative patients, 3  
for end-point measurement, in deep venous thrombosis prevention studies, 41  
leg test, for pulmonary embolism diagnosis, cost-effectiveness of, 15  
for pulmonary embolism, in outpatients, 25
- Oligonucleotide primer sets, DNA sequence analysis of protein S deficiency and, 155
- Oligopeptides, as thrombin indicator, 523
- Oligosaccharides, glycosaminoglycan, MALDI mass spectrometry as tool for characterizing, 465
- Peptidomimetics, as thrombin indicator, 523
- Phenotype, genotype correlated with, molecular biology of blood coagulation and, 313
- Phosphatidylcholine, intrauterine growth restriction induced by, in mice, prevention by activated protein C, 99
- Phosphatidylserine, intrauterine growth restriction induced by, in mice, prevention by activated protein C, 99
- Phospholipids  
anticoagulant pathway responses in disseminated intravascular coagulation and, 619  
platelet-derived, activated, as thrombogenic factors in intraplacental coagulation, 107  
vesicle preparation, 99
- PIVKA-II, variation of cord blood levels, throughout gestation, 87
- Placenta  
retroplacental hemorrhage and, localized cold stimulation related to, in rats, 79  
vitamin K transport through, 93
- Placental circulation, intraplacental coagulation in intrauterine growth restriction and, 107
- Plasma  
defibrinated, thrombin generation in, in mice, 99  
platelet-free, preparation of, 99
- Plasma proteins, adhesion of, regioselectively sulfated and acetylated coatings of biomaterials to reduce, 445
- Plasminogen activator inhibitor type 1, fibrinolysis in disseminated intravascular coagulation and, 633
- Plasminogen activators  
disseminated intravascular coagulation in sepsis and, 577  
fibrinolysis in disseminated intravascular coagulation and, 633
- Platelet antigens, in alloimmune thrombocytopenia, 245
- Platelet counting  
predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137  
in thrombocytopenia  
automated, 229, 237  
immune, 253, 269  
rapid manual method for, 237
- Platelet-free plasma, preparation of, 99
- Platelets  
adhesion of  
to collagen dependent on von Willebrand factor, saratin inhibition of, 337  
regioselectively sulfated and acetylated coatings of biomaterials to reduce, 445  
effect of thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonist in ex vivo human experimental thrombosis model and, 531  
effects of heparin-binding protein on function of, 495  
transfusions of, for acute leukemia, 593
- Polymerase chain reaction  
DNA sequence analysis of protein S deficiency and, 155  
of recombinant hirudin, 349
- Polymorphisms  
molecular biology of blood coagulation and, 313  
T235 variant of angiotensin gene as risk factor for preeclampsia and, 143
- Postthrombotic syndrome, clinical course of, 9
- Preeclampsia  
angiospastic syndrome of pregnancy and, 131  
termination of pregnancy complicated by, predictive values of coagulation/fibrinolysis parameters for, 137  
T235 variant of angiotensin gene as risk factor for, 143  
variation of des-gamma-carboxyprothrombin levels in cord blood throughout gestation and, 87
- Pregnancy. *See also* Fetus  
angiospastic syndrome of, 131  
disseminated intravascular coagulation during, 161

- Pregnancy (*cont.*)  
 tissue factor pathway in disseminated intravascular coagulation and, 605  
 factor XII deficiency related to recurrent miscarriage and, 115  
 intrauterine growth restriction and intraplacental coagulation in, 107  
 in mice, phosphatidylserine-induced, activated protein C prevention of, 99  
 loss of. *See* Miscarriage  
 preeclampsia in. *See* Preeclampsia  
 variation of des-gamma-carboxyprothrombin levels in cord blood throughout, 87  
 venous thromboembolism in, clinical study of, 149
- Protein C  
 activated  
 obstetrical disseminated intravascular coagulation and, 161  
 prevention of phosphatidylserine-induced intrauterine growth restriction in mice, 99  
 deficiency of, recurrent pregnancy loss associated with thrombophilia and, 121  
 in disseminated intravascular coagulation, 667  
 anticoagulant pathway responses and, 619  
 cytokine regulation of disseminated intravascular coagulation and, 639
- Protein S, deficiency of  
 DNA sequence analysis of, 155  
 recurrent pregnancy loss associated with thrombophilia and, 121
- Protein Z, 551
- Proteolysis, disseminated intravascular coagulation in acute leukemia and, 593
- Prothrombin time, in disseminated intravascular coagulation, 653
- Puerperium, venous thromboembolism in, clinical study of, 149
- Pulmonary embolism  
 clinical probability of, 25  
 diagnosis of  
 contrast-enhanced spiral computed tomography for, 33  
 cost-effectiveness of diagnostic strategies for, 15  
 by sequential noninvasive tools, 25  
 in pregnancy and puerperium, clinical study of, 149  
 suspected, alternative diagnoses for, 33
- Quality of life, in idiopathic thrombocytopenic purpura, in children, 277
- Recombinant tissue-type plasminogen activator, in children, 169
- Renal failure, chronic, von Willebrand factor in diarrhea-associated hemolytic-uremic syndrome and, 287
- Renal function, monitoring patients treated with low molecular weight heparin and, 519
- Rhesus hemolytic disease, thrombopoietin in, 220
- Saratin, production and characterization, 337
- Schwachman syndrome, thrombopoietin in, 220
- Schwartzman reaction, tissue factor expression in, 605
- Screening, for alloimmune thrombocytopenia, 245
- Sepsis  
 disseminated intravascular coagulation in, 577  
 anticoagulant factor concentrates in, 667  
 fibrinolysis in, 633  
 neonatal, thrombopoietin in, 220
- Septicemia, tissue factor pathway in disseminated intravascular coagulation and, meningococcal, 605
- Septic shock, disseminated intravascular coagulation in, 577
- Serine protease inhibitors, synthetic, obstetrical disseminated intravascular coagulation and, 161
- Shiga toxins, role in hemolytic-uremic syndrome associated with Enterohemorrhagic *Escherichia coli*, 207
- Single-gene disorders, molecular biology of blood coagulation and, 313
- Smooth muscle cells, cellular effects of Factor Xa on vascular smooth muscle cells, inhibition by heparins, 489
- Spiral computed tomography  
 for pulmonary embolism diagnosis, 25, 33  
 for thromboembolism diagnosis, in medical intensive care unit, 47
- Structure-function relationships, molecular biology of blood coagulation and, 313
- Sulfation  
 combined quantitative magnetic resonance spectroscopy for characterization of heparin preparations, 473  
 sulfation effects on antithrombin-thrombin/Factor Xa interactions in semisynthetic low molecular weight heparin, 483
- Surgery, deep venous thrombosis following, noninvasive diagnosis of, 3
- Sympathetic nerve, retroplacental hemorrhage and, localized cold stimulation related to, in rats, 79
- Systemic inflammatory response syndrome, disseminated intravascular coagulation and, 585
- Thermography, for cold stress testing, 79
- Thrombin  
 generation in defibrinated plasma, from mice, determination of, 99  
 tissue factor pathway in disseminated intravascular coagulation and, 605
- Thrombin-antithrombin complex, predictive values of coagulation/fibrinolysis parameters for termination of pregnancy complicated by severe preeclampsia and, 137
- Thrombin inhibitors  
 development of, 523  
 direct, clinical monitoring of, 537  
 effect in ex vivo human experimental thrombosis model, 531
- Thrombocythemia, essential, thrombopoietin in, 222
- Thrombocytopenia  
 in children  
 alloimmune, in fetus and newborn, 245  
 automatic counting procedures in, 229, 237  
 heparin-induced, 293  
 immune, nontreatment of, 269  
 immune, retrospective and prospective survey in Germany, 253  
 platelet counting in, rapid manual method for, 237



- thrombopoietin in, 215
- treatment of, 222
- heparin-induced
  - effects of heparin-binding protein on blood coagulation and platelet function and, 495
  - hirudins for prophylaxis and treatment of thromboembolism and, 543
- Thromboembolism. *See also* Deep venous thrombosis; Thrombosis; Venous thromboembolism
  - clinical monitoring of hirudin and direct thrombin inhibitors and, 537
  - in medical intensive care unit, 47
  - prophylaxis of, 47
  - treatment of, 47
- Thrombolytic therapy, recombinant tissue-plasminogen activator in children and, 169
- Thrombophilia
  - protein Z and, 551
  - recurrent pregnancy loss associated with, 121
  - venous thromboembolism in pregnancy and puerperium and, clinical study of, 149
- Thrombopoietin, in thrombocytopenias of childhood, 215
- Thrombosis. *See also* Deep venous thrombosis; Thromboembolism; Venous thromboembolism
  - effect of thrombin inhibitors and glycoprotein IIb/IIIa receptor antagonist in ex vivo human experimental thrombosis model and, 531
  - intraplacental coagulation in intrauterine growth restriction and, 107
  - protein S deficiency and, DNA sequence analysis of, 155
  - recombinant tissue-plasminogen activator in children and, 169
- Tissue factor pathway inhibitor
  - circulating in plasma, molecular weight-dependent influence of heparin on form of, 503
  - in disseminated intravascular coagulation, 667
  - tissue factor pathway in disseminated intravascular coagulation and, 605
- Tissue-type plasminogen activator, production in *Escherichia coli*, 325
- Trauma
  - disseminated intravascular coagulation associated with, 585
  - tissue factor and, 605
- Trisomy 21, with myeloproliferation, thrombopoietin in, 220
- Ultrasound
  - in deep venous thrombosis
    - compression, 9
    - for end-point measurement, 41
    - in postoperative patients, 3
  - for pulmonary embolism diagnosis
    - compression, 25
    - repeat, cost-effectiveness of, 15
  - for thromboembolism diagnosis, in medical intensive care unit, 47
- Umbilical cord, variation of des-gamma-carboxyprothrombin levels in cord blood and, throughout gestation, 87
- Urinary trypsin inhibitor, synthetic, 161
- Uterine blood flow, localized cold stress effects on, in rats, 79
- Uterine contraction
  - factor XII deficiency related to recurrent miscarriage and, 115
  - localized cold stress effects on, in rats, 79
- Vasospasms, angiospastic syndrome of pregnancy and, 131
- Venography
  - contrast, for thromboembolism diagnosis, in medical intensive care unit, 47
  - for end-point measurement, in deep venous thrombosis prevention studies, 41
- Venous thromboembolism. *See also* Deep venous thrombosis; Thromboembolism; Thrombosis
  - hirudins for prophylaxis and treatment of, 543
  - molecular biology of blood coagulation and, 313
  - in pregnancy and puerperium, clinical study of, 149
- Ventilation-perfusion lung scans
  - for pulmonary embolism diagnosis, 25
  - cost-effectiveness of, 15
  - for thromboembolism diagnosis, in medical intensive care unit, 47
- Vitamin K
  - deficiency of, during perinatal and infantile period, 93
  - protein Z and, 551
  - variation of des-gamma-carboxyprothrombin levels in cord blood throughout gestation and, 87
- von Willebrand disease, molecular biology of blood coagulation and, 313
- von Willebrand factor
  - in diarrhea-associated hemolytic-uremic syndrome, 287
  - platelet adhesion to collagen dependent on, saratin inhibition of, 337
  - recombinant, preclinical development of, 395
- Wiskott-Aldrich syndrome, thrombopoietin in, 220